| Autor: |
Rodriguez-Jimenez NA; Departamento de Fisiología, Centro Universitario de Ciencias de La Salud (CUCS), Universidad de Guadalajara (U. de G.), Guadalajara, JAL, Mexico., Perez-Guerrero EE; Instituto de Investigación en Ciencias Biomédicas (IICB), CUCS, U. de G, Guadalajara, JAL, Mexico., Gamez-Nava JI; Unidad Biomédica 02, Hospital de Especialidades, Centro Médico Nacional de Occidente (CMNO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, JAL, Mexico.; Programa de Doctorado en Farmacología y Programa de Doctorado en Salud Publica, CUCS, U. de G, Sierra Mojada 950, 44340, Guadalajara, JAL, Mexico., Sanchez-Mosco DI; Centro de Rehabilitación E Inclusión Infantil Teletón (CRIT) Guerrero, Acapulco de Juárez, Gro, Mexico., Saldaña-Cruz AM; Departamento de Fisiología, Centro Universitario de Ciencias de La Salud (CUCS), Universidad de Guadalajara (U. de G.), Guadalajara, JAL, Mexico., Alcaraz-Lopez MF; Departamento de Medicina Interna-Reumatología, Hospital General de Zona 45, IMSS, Guadalajara, JAL, Mexico., Fajardo-Robledo NS; Laboratorio de Investigación Y Desarrollo Farmacéutico, CUCEI, U. de G, Guadalajara, JAL, Mexico., Muñoz-Valle JF; Instituto de Investigación en Ciencias Biomédicas (IICB), CUCS, U. de G, Guadalajara, JAL, Mexico., Bonilla-Lara D; Programa de Doctorado en Farmacología y Programa de Doctorado en Salud Publica, CUCS, U. de G, Sierra Mojada 950, 44340, Guadalajara, JAL, Mexico., Diaz-Rizo V; Departamento de Disciplinas Filosófico, Metodológicas E Instrumentales, CUCS, U. de G., Guadalajara, JAL, Mexico., Gonzalez-Lopez L; Programa de Doctorado en Farmacología y Programa de Doctorado en Salud Publica, CUCS, U. de G, Sierra Mojada 950, 44340, Guadalajara, JAL, Mexico. lauraacademicoudg@gmail.com.; Departamento de Medicina Interna-Reumatología, Hospital General Regional 110, IMSS, Guadalajara, JAL, Mexico. lauraacademicoudg@gmail.com.; Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Sierra Mojada 950, Col. Independencia, C.P., 44340, Guadalajara, JAL, Mexico. lauraacademicoudg@gmail.com. |
| Abstrakt: |
An important goal in the management of systemic lupus erythematosus (SLE) is the prediction of relapses. This study assesses whether anti-nucleosome antibodies (anti-NCS) increase the risk of renal relapse in inactive SLE. A prospective cohort of 115 patients with inactive SLE (M-SLEDAI ≤ 2) were followed for 12 months to assess the development of relapse (increase of M-SLEDAI ≥ 4) and specific renal flare (renal SLEDAI ≥ 4). At baseline, we identified potential risk factors for relapse, including anti-NCS. At baseline, 18 (16%) of the 115 patients with inactive SLE were anti-NCS positive. At the 12-month follow-up, anti-NCS-positive patients had a higher incidence of renal relapse compared to anti-NCS-negative patients (38.9% vs 13.4%, respectively). In Cox regression analysis, after adjusting for age, disease duration, anti-dsDNA, and immunosuppressive drugs, the presence of anti-NCS positivity at baseline increased the risk of renal relapse (HR: 5.31, 95% CI 2.03-13.92). Nevertheless, there were no differences in the incidence of other relapses in anti-NCS-positive versus anti-NCS-negative. Our results indicate that in inactive SLE, anti-NCS determination can be useful for identifying patients with a higher risk of developing renal relapse. Interestingly, this study identified that continued use of oral immunosuppressive therapy in patients with inactive SLE can reduce the risk of renal relapse. |
